In patients with chronic liver disease, the most common adverse reactions (≥ 3%) were pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.
In patients with chronic immune thrombocytopenia, the most common adverse reactions (≥ 10%) were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.
from FDA,2021.06
The side effects of Avatrombopag are generally manageable, with most being mild ···【more】
Release date:2026-02-24Recommended:224
Avatrombopag is an oral medication used to treat thrombocytopenia (low platelet ···【more】
Release date:2026-02-24Recommended:214
Avatrombopag is an innovative drug that has shown significant results in the tre···【more】
Release date:2025-02-06Recommended:460
Avatrombopag is a novel thrombopoietin receptor agonist, and its safety and side···【more】
Release date:2025-02-06Recommended:426
Avatrombopag is a drug used to treat thrombocytopenia, but its side effects are ···【more】
Release date:2025-02-05Recommended:390
Avatrombopag is a drug used to treat thrombocytopenia, but its use may be accomp···【more】
Release date:2025-02-05Recommended:359